Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

Next Previous
Trial Profile

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Rintatolimod (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DURIPANC

Most Recent Events

  • 27 Mar 2025 According to an AIM ImmunoTech media release, last patient enrollment in phase 2 expected in Q2/Q3 2026.
  • 27 Mar 2025 According to an AIM ImmunoTech media release, Erasmus Medical Center Safety Committee granted approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM's Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of late-stage pancreatic cancer (DURIPANC).
  • 11 Mar 2025 According to an AIM ImmunoTech media release, the company will participate in the Virtual Investor Top 5 for 25 On-Demand Conference to discuss progress in late-stage pancreatic cancer treatment, focusing on significant advancements in the Phase 1b/2 DURIPANC trial at Erasmus Medical Center in the Netherlands.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top